Skye Bioscience (SKYE) Appoints Paul Grayson as Chairman
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
October 29, 2024 7:00 AM EDTSAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (Skye), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced the Board has appointed independent director Paul Grayson as Skyes new Chairman of the Board, effective October 25, 2024. Mr. Grayson currently serves as a member of Skyes Audit, Compensation and Nominating and Corporate Governance Committees. Punit Dhillon, Skyes Chief Executive Officer, will continue to serve as a member of the Board.
Punit Dhillon, Skyes Chief Executive Officer and former Chairman of the... More



